title: Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica.
abstract: Effector mechanisms resulting from alternative complement pathway (ACP) activation cannot act efficiently against Yersinia enterocolitica serotype O3, as indicated by poor C3 to C9 consumption and by survival in EGTA (ethyleneglycoldiaminetetraacetic acid) Mg-serum. These results were not influenced by the lack or presence of plasmid-encoded outer membrane proteins or lipopolysaccharides (LPS) with different amounts of side chains or by treatment of the bacteria with pronase or neuraminidase. Surface modulation of Y. enterocolitica with polyclonal immunoglobulin G or the immunoglobulin G fragments F(ab')2 and Fab always converted Y. enterocolitica to a high ACP activator, with strong C3 to C9 consumption and surface deposition of activated C3. Killing of Y. enterocolitica as a result of antibody-mediated ACP activation was observed only with bacteria grown at 22 degrees C but not with bacteria from 37 degrees C cultures. The expression of complement resistance in Y. enterocolitica grown at 37 degrees C was not influenced by the presence or absence of plasmids. Using different monoclonal antibodies (MAb), we found that MAb with LPS specificity mediated ACP activation, whereas MAb specific for different plasmid-encoded outer membrane proteins were ineffective, despite surface binding. These results suggest a major inhibitory role of LPS on ACP activation which was neutralized by LPS-specific antibodies.
authors.affiliation: Institut für Klinische Mikrobiologie, Universität Erlangen-Nürnberg, Federal Republic of Germany.
authors.forename: E
authors.initials: E
authors.lastname: Wachter
authors.forename: V
authors.initials: V
authors.lastname: Brade
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000502:physiology*; D000911:Antibodies, Monoclonal / Q000502:physiology*; D000937:Antigen-Antibody Reactions; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology / Q000502:physiology*; D001665:Binding Sites; D001770:Blood Bactericidal Activity; D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism; D003170:Complement Pathway, Alternative; D005260:Female; D006168:Guinea Pigs; D006461:Hemolysis; D007128:Immunoglobulin Fragments / Q000502:physiology; D007074:Immunoglobulin G / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D009439:Neuraminidase / Q000494:pharmacology*; D011402:Pronase / Q000494:pharmacology*; D011817:Rabbits; D015008:Yersinia enterocolitica / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D001425:Bacterial Outer Membrane Proteins; D003176:Complement C3; D007128:Immunoglobulin Fragments; D007074:Immunoglobulin G; D009439:Neuraminidase; D011402:Pronase